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Point-of-care microneedle diagnostics 
\ 
Abstract 
The coronavirus disease 2019 (COVID-19) pandemic has taught us much about our weaknesses in the 
management of infectious disease outbreaks. A key lesson has been the need for more effective point-
of-care diagnostic tools that produce not only rapid and reliable results but also facilitate decentralised 
testing to avoid overwhelming central test facilities when demand peaks in an outbreak. Microneedle 
devices can be inserted painlessly into the skin to detect biomolecules in the epidermal and dermal 
layers. They have been used to identify biomarkers in both the interstitial fluid and capillary blood. 
Importantly, they are amenable to self-administration. In this article, we provide an overview of existing 
microneedle-based diagnostic technologies and discuss how they may be built upon to provide effective 
diagnostic tools for infectious diseases. 
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Purpose & Rationale 
In late January 2020, during the peak of the 
lunar New Year travel season, the Chinese gov-
ernment took the extraordinary measure of 
locking down entire cities to contain a new and 
highly contagious viral respiratory disease. The 
media reports at the time provided the first in-
dications of the unprecedented public health 
challenges posed by the coronavirus disease 
2019 (COVID-19) outbreak. As hospitals expe-
rienced a sudden influx of potentially infected 
patients, many patients waited to be seen in 
overcrowded hospital lounges.  
By March 11, 2020, the infection had spread 
rapidly across multiple continents, prompting 
the World Health Organization (WHO) to de-
clare a pandemic. Since then, the scenes of 
overstretched public health systems that are 
struggling to meet the sudden spike in demand 
for COVID-19 diagnoses have been replicated 
in many countries, even among the richest 
economies. The COVID-19 outbreak has up-
ended the common perception that infectious 
diseases are a problem of the developing world 
and exposed many deficiencies in current diag-
nostic strategies for infectious diseases.  
Here, we discuss the lessons to be learned 
from this episode and how emerging micronee-
dle diagnostic technologies could potentially 
help avert similar challenges in the future. 
Introduction & Discussion 
In recent decades, several infectious disease 
outbreaks have caused major disruptions in 
both the developed and developing regions of 
the world. For example, epidemics of dengue 
fever, the Ebola virus disease, and the Zika vi-
rus diseases ravaged Africa, Asia, and South 
America between 2014 and 2016. The world 
has also witnessed successive outbreaks of res-
piratory viral infections, including various 
strains of the influenza virus, as well as corona-
viruses that caused the severe acute respiratory 
syndrome (SARS, 2002), the Middle East res-
piratory syndrome (MERS, 2012), and the 
COVID-19 (2019) pandemic that still grips the 
world at the time of this writing. In 2016, mor-
tality rates by infectious diseases accounted for 
approximately 8.5 million deaths globally, 
more than half of which were recorded in low-
income countries [1]. 
Infectious disease outbreaks are not new. The 
1918 Spanish flu remains one of the most dev-
astating outbreaks in modern history [2], and 
infectious disease outbreaks have been linked 
to the collapse of entire civilisations [3]. While 
modern-day healthcare systems across the 
world have adapted to manage gradual develop-
ments of public health threats, they are gener-
ally ill-equipped to respond to sudden out-
breaks of infectious diseases. For the past few 
years, infectious disease pandemics and a lack 
of access to affordable diagnostic tools have 
featured every year on WHO’s annual list of 
predicted health challenges and threats to 
global health [4]–[6]. However, despite ample 
warnings, the world continued to be underpre-
pared for an infectious disease pandemic.  
Then, in 2019, the threat materialised sooner 
than expected. COVID-19 was first reported in 
Wuhan, China, in December 2019 and rapidly 
spread throughout the world. As of May 27, 
2020, the global death toll from COVID-19 
stood at over 350,000, with approximately 
three-quarters of the deaths in high-income 
countries, including the United States, the 
United Kingdom, Italy, Spain, France, and Bel-
gium [7], [8]. However, the number of tests per-
formed per capita remained generally below 
6% [8]. Amid calls for more tests to be done [9], 
[10], governments admitted that testing capac-
ity was limited [11], [12].  
These examples illustrate that it is not just in 
developing and underdeveloped countries that 
infectious disease diagnosis can be a challenge. 
Developed countries, too, face challenges due 
to centralised—albeit state-of-the-art—test fa-
cilities and limited resources that can be over-
whelmed in the case of a severe infectious dis-
ease outbreak.  
What do we need for effective diagnosis 
in an infectious disease outbreak? 
Effective diagnostics should be at the heart of 
our global strategy for tackling infectious dis-
eases so that infected individuals can be quickly 
identified and treated, to effectively monitor 
and control disease transmission. Point-of-care 
diagnostics is medical testing administered near 
or at the point of patient care. Point-of-care di-
agnostic tests for infectious disease should ful-
fil the ASSURED criteria: be affordable, sensi-
tive, specific, user friendly, rapid and robust, 
equipment-free, and deliverable to end-users 
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[13]. Some current point-of-care tests already 
meet these criteria to various extents [14], but 
some significant challenges remain. 
Current diagnostic protocols for most infec-
tious diseases hinge on the collection of bodily 
fluids for laboratory tests that require skilled 
personnel and expensive equipment. Many of 
these samples require “cleaning up” to remove 
cellular debris and assay inhibitors before the 
target marker/molecule can be processed. The 
prepared sample is then analysed using state-of-
the-art techniques such as the polymerase chain 
reaction (PCR) or immunoassays to detect nu-
cleic acids, pathogenic antigens, or host anti-
bodies. These complex procedures restrict the 
use of such tests to central test facilities like 
hospitals and specialist laboratories, requiring 
the public to travel to clinics and hospitals to be 
tested. Herein lie several problems. First, cen-
tralised test facilities limit the accessibility of 
the test. Second, the diagnostic procedure ne-
cessitates close contact between potentially in-
fected individuals and healthcare professionals, 
which increases the risk of disease transmission 
to key personnel. Third, in the case of an infec-
tious disease outbreak, requiring potentially in-
fected individuals to travel to test facilities de-
feats the objective of any quarantine measures 
that may be in place to help contain the disease. 
We have witnessed these problems play out in 
the COVID-19 pandemic where strict travel re-
strictions were imposed in many regions of the 
world, and internal lockdown measures were 
implemented to encourage the public to stay at 
home. Meanwhile, the global demand for criti-
cal personal protective equipment and accurate 
diagnostic tests skyrocketed while supply 
chains were disrupted, leading to acute short-
ages. 
To overcome these limitations, more testing 
tools that are suitable for home use need to be 
developed. In addition to meeting the 
ASSURED criteria above, such tests should 
ideally allow self-diagnosis by being self-ad-
ministrable and self-analysable. As an example, 
the home pregnancy test provides an ideal plat-
form to which infectious disease diagnostics 
can aspire. The ability to self-diagnose infec-
tions rapidly and reliably will not only acceler-
ate diagnosis and treatment but also alleviate 
the strain on central test laboratories and health 
workers. Another advantage is that the public 
would not need to travel to overcrowded cen-
tralised healthcare facilities for testing, risking 
that they might infect others or be infected in 
the process.  
However, such a test kit will still rely on a 
functioning supply chain and distribution net-
work to work effectively. While such a diagnos-
tic kit may seem far-fetched for infectious dis-
ease outbreaks, microneedle-based diagnostic 
platforms promise the technological leap neces-
sary to realise this advancement. 
Microneedle diagnostic platforms 
Typically presented as a skin patch, micronee-
dles are arranged into a grid array with solid or 
hollow needle shafts <1 mm long and up to a 
few hundred micrometres wide, projecting per-
pendicularly from the patch surface (Figure 1). 
When applied on the skin, the microneedles cre-
ate micropores in the superficial skin tissue. 
The application of microneedle patches has 
been shown to be painless and better accepted 
by users compared with conventional hypoder-
mic needles [15]–[18]. Microneedles are short 
enough to penetrate only the superficial skin 
layers, avoiding nerve endings and major blood 
vessels, while still accessing analyte-rich inter-
stitial fluid (ISF) or capillary blood. ISF is an 
attractive target because it contains many of the 
same constituents as blood plasma and suction 
blister fluid at clinically relevant concentrations 
[19]–[21]. Encouragingly, it has already been 
demonstrated in the context of drug delivery 
that microneedle patches are self-administrable 
[22]–[24], which paves the way for self-admin-
istration of microneedle-based diagnostics. 
Microneedle diagnostic platforms have a long 
history of development for applications such as 
glucose monitoring, but infectious disease de-
tection is an emerging application, and there are 
reasons to be optimistic about this potential use. 
Fueled by advances in the underpinning tech-
nologies, microneedle diagnostic technologies 
have recently witnessed remarkable innova-
tions. For example, until recent years, PCR was 
performed almost exclusively in central facili-
ties with specialist personnel and thermocy-
cling equipment [25]–[27]. The emergence of 
isothermal PCR has allowed nucleic acids to be 
amplified close to body temperature [27]–[31]. 
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Figure 1: (A) An exemplar microneedle array made of polylactic acid. The boxed region in (A) is enlarged in (B) to show a 
single microneedle. (C) Micropores created by a microneedle array in the skin, highlighted by a blue dye (methylene blue) for 
ease of visualisation. Scale bars: (A, C) 1 mm; (B) 250 µm. 
This has, in turn, inspired the development of 
a wearable microneedle patch to detect the Ep-
stein-Barr virus which amplifies the target viral 
circulating-free deoxyribonucleic acid (DNA) 
in situ by isothermal PCR between 32°C and 
37°C [32]. This practice paves the way for us-
ing microneedle diagnostic technologies to de-
tect a host of other infectious diseases with 
known circulating-free DNA targets, including 
malaria and tuberculosis [33], [34]. Recent ad-
vances in other areas closely related to skin bi-
osensing and bioanalysis, such as nanotechnol-
ogy and 3D printing, will likely further enhance 
microneedle-based diagnostics [35].  
To understand how microneedles can be lev-
eraged for infectious disease diagnosis, we need 
to dissect how they work. Broadly speaking, 
current microneedle diagnostic systems operate 
in one of the following ways: (1) they extract 
biofluids or target analytes from the skin for in 
vitro testing or (2) they perform in situ biosens-
ing of target analytes in the skin (Figure 2).  
 
 
Figure 2: Common modes of action of current microneedle diagnostic platforms. (A, B) Biofluid extraction can be achieved 
using hollow or solid microneedles. (C) Specific target analyte capture can be achieved using immobilised probes on mi-
croneedles. A multiplex system designed to detect analytes 1 and 2 simultaneously is shown. (D) Electrochemical microneedle 
biosensors convert a redox reaction into an electric signal. 
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The mode of action depends largely on the tar-
get analyte, which influences the choice of the 
downstream analytical procedure. These de-
vices may be coupled with conventional analyt-
ical equipment, or sophisticated lab-on-a-chip 
analytical systems may be integrated into the 
microneedle diagnostic platforms. In either 
case, the hallmark of these microneedle-based 
diagnostic technologies is their ability to easily 
access skin biofluids (e.g., ISF and capillary 
blood) with minimal invasiveness. 
Microneedles for biofluid extraction 
Biofluids can be extracted from the skin using 
hollow or solid microneedles, the former hav-
ing been particularly well demonstrated in the 
context of microneedle-based glucose biosen-
sors. Hollow microneedles have a hollow nee-
dle shaft and a surface orifice. Biofluid uptake 
through the orifice into the hollow microneedle 
shaft could occur by capillary action, or biofluid 
flow could be induced through a microfluidic 
system, usually by applying negative pressure 
[37]–[42]. This technique has been used to ex-
tract dermal ISF using hollow silicon micronee-
dles for on-chip detection (see “Microneedles 
for in situ biosensing,” below), as well as off-
chip nucleic acid profiling to identify potential 
disease biomarkers, in conjunction with con-
ventional sample processing techniques and 
PCR-based analysis [43]. One study reported an 
ISF uptake rate of 1 µL/s [39]. 
Solid microneedles, on the other hand, do not 
have a surface orifice or a hollow shaft. The ap-
plication of solid microneedles encourages ISF 
to migrate to the skin’s surface. ISF can then be 
absorbed into a sheet of paper for subsequent 
biomarker analysis [44], [45]. Alternatively, 
hydrogel-forming microneedles swell upon in-
sertion into the dermal interstitium and absorb 
ISF. Downstream processing of the hydrogel 
microneedle array by centrifugation liberates 
the analytes of interest, which can then be quan-
tified using conventional techniques such as 
high-performance liquid chromatography [46]–
[48]. Porous microneedle arrays contain inter-
connected pores in the body of the micronee-
dles, which allow them to absorb skin biofluids 
by capillary action. The biofluids can then be 
recovered from the microneedles by centrifuga-
tion [49], [50]. Biofluid flow can also be ac-
tively induced. In one study using stainless steel 
solid microneedles and a suction pump, 100 µL 
of capillary blood was extracted through micro-
fluidic channels into a collection chamber in 3 
minutes [51]. 
Biofluid extraction using microneedles is ad-
vantageous primarily because it is minimally 
invasive and quick. However, a major chal-
lenge of this approach is the limited volume of 
ISF or capillary blood extracted, which is typi-
cally in the nanoliter-to-microliter range. 
Larger sample volumes are usually required for 
current lab-based analytical techniques or com-
mercially available testing kits [52]–[57]. 
While it is possible to extend the microneedle 
length to sample larger volumes directly from 
larger blood vessels, doing so inevitably in-
creases the technique’s invasiveness and com-
plexity, diminishing the advantages of being 
minimally invasive and self-administrable. 
Also, hollow microneedles can become clogged 
with tissue debris, although some advances 
have been made to resolve this issue [58]. In 
comparison, solid microneedles are simpler in 
design and hence are likely to be easier and 
cheaper to manufacture at scale. However, the 
downstream processes to liberate the analyte of 
interest from solid microneedle systems typi-
cally dilute the sample, thus reducing the ana-
lyte concentration. Coupling such microneedle 
biofluid extraction devices to current analytical 
equipment may prove challenging for low-
abundance analytes. 
Moreover, the extracted samples still require 
purification to isolate the analyte of interest 
prior to analysis. This may be advantageous as 
it could be possible to perform the analysis us-
ing existing analytical facilities, so the barrier 
to adoption may be low. Nonetheless, it will 
rely on specialist personnel and central analyti-
cal facilities, which may prove to be a bottle-
neck in achieving the rapid diagnosis desired. 
To decentralise the analytical step, a lab-on-a-
chip microneedle diagnostic platform with inte-
grated analytics is desirable. On-chip detection 
has already been demonstrated for metabolites, 
including glucose and cholesterol using mi-
croneedle devices with integrated colourimetric 
assays that promise to be simple, quick, and 
economical. For example, biofluids have been 
absorbed into paper strips containing reagents 
that undergo a measurable color change in the 
presence of the target analyte [59], [60]. This 
style of point-of-care test can easily be multi-
plexed by incorporating multiple test strips with 
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different detection reagents. It may be possible 
to adapt this strategy for infectious disease di-
agnosis, for example, as an on-chip colourimet-
ric immunoassay for detecting pathogenic anti-
gens. 
Microneedles for analyte capture 
Some microneedle devices can extract only 
specific target analytes from the skin without 
removing any perceivable amount of biofluid. 
This technique is advantageous over biofluid 
extraction as it eliminates the need for sample 
purification. Target analytes with structural 
motifs amenable to molecular recognition, such 
as proteins and nucleic acids, may be extracted 
using this technique.  
One embodiment of this technology uses an-
tigen-specific immunocapture. Capture anti-
bodies immobilised on to the surface of solid 
microneedles have successfully captured path-
ogenic antigens, host antibodies, and cytokines 
from the skin at concentrations comparable to 
the assay limits of conventional immunoassays 
[61]–[66]. Target capture at detectable levels in 
under 1 minute has been demonstrated [67]. By 
immobilising different capture antibodies on to 
different microneedle surfaces on a given array, 
multiplex detection (i.e., simultaneous detec-
tion of multiple analytes) and internal assay 
controls can be incorporated [65]. Post-capture 
antigen confirmation and quantification can be 
accomplished using conventional techniques 
such as colourimetry and fluorimetry. The de-
velopment of more facile and portable analyti-
cal techniques, such as paper-based visual anal-
ysis [65], [66], may facilitate self-analysis by 
lay users. Longer application times of an im-
munocapture microneedle patch may facilitate 
analyte detection at lower concentrations but 
may prolong the test duration. A delicate bal-
ance will likely need to be struck between these 
considerations.  
Similarly, peptide nucleic acids immobilised 
on the surface of hydrogel microneedles have 
successfully captured target micro-ribonucleic 
acid (microRNA) sequences in skin ISF by hy-
bridisation [68]. The captured microRNA was 
detected and quantified “on-patch” using fluo-
rescently tagged DNA probes, or “off-patch” by 
liberating the hybridised microRNA complexes 
via a photocleavable linker molecule in the pep-
tide nucleic acid probe. This method of nucleic 
acid extraction and purification promises sig-
nificant time and cost savings over conven-
tional methods. 
These techniques rely on a high-quality sur-
face for probe (i.e., capture antibody or peptide 
nucleic acid probe) immobilisation, as well as 
strong and specific intermolecular interactions 
between the probe and target analyte. There-
fore, the microneedle fabrication technique 
should ideally promote high-density probe im-
mobilisation and optimal probe orientation and 
minimise non-specific binding while ensuring 
that the microneedle surface is biocompatible. 
Various immobilisation strategies are available, 
and their success will depend largely on the 
properties of the initial deposition surface [67], 
[69]. Furthermore, increasing the number of 
microneedles per array will increase the surface 
area for probe deposition, thus increasing de-
vice sensitivity and its multiplexing potential. 
Microneedles for in situ biosensing  
Electrochemical microneedle biosensors can 
detect redox reactions induced by the analyte of 
interest in situ and produce electrical measure-
ments proportional to the analyte concentration. 
These technologies can comprise hollow or 
solid microneedles and have been explored 
mainly for the detection of small molecules, in-
cluding glucose, lactate, uric acid, nitric oxide, 
ascorbic acid, cholesterol, and levodopa [70]–
[74]. Hollow microneedles are typically used to 
extract and channel biofluids to the electrodes 
of the electrochemical cell, while solid mi-
croneedles usually serve as the electrodes them-
selves. 
The main advantage of in situ biosensing is 
the real-time or near-real-time analyte detec-
tion, without the need for sample processing or 
storage. However, electrochemical microneedle 
biosensors demand that the analyte be either 
electroactive or coupled to a suitable intermedi-
ary or transducer system capable of converting 
a non-electrical event into an electrical signal. 
For example, the vast majority of glucose bio-
sensors do not detect glucose directly but incor-
porate glucose oxidase as an enzymatic inter-
mediary. The lack of either option in the analyte 
is likely to be the key factor limiting the appli-
cation of these microneedle biosensors.  
Analyte detection does not have to be electro-
chemical in nature, however. For example, 
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Smart and Subramanian [74] described a glu-
cose biosensor based on glucose dehydrogen-
ase-formazan chemistry, where glucose con-
centration was measured by optical absorbance. 
Although the hollow “microneedles” used in 
that study were 2 mm long and so do not fit our 
definition above, it was nonetheless an excel-
lent demonstration of on-chip analyte detection 
using a non-electrochemical method.  
The literature on in situ biosensors for infec-
tious diseases is scarce. However, a hollow mi-
croneedle device was developed to extract ISF 
from the skin and transfer it into a chamber con-
taining either immobilised anti-CD4 T+ cell an-
tibodies (to detect human immunodeficiency 
virus or HIV) or antibodies against Ebola cap-
sid glycoproteins (to detect Ebola virus). The 
cell/ligand binding events were measured by 
electrical impedance [75]–[77].  
Conclusions 
The Global Preparedness Monitoring Board has recently highlighted two pitfalls in the global health 
emergency response strategy in relation to disease diagnostics: first, national capacities for diagnostics 
research and development are underdeveloped, and second, diagnostics has received fewer investments 
than other areas, such as a vaccine, basic research, and therapeutics [78]. Current testing kits for infec-
tious diseases can be expensive, require trained medical personnel, and rely on limited medical infra-
structure that is typically centralised. Due to resource limitations, these characteristics could hinder 
disease control efforts in an infectious disease outbreak.  
Decentralised, self-administrable, and self-diagnosing point-of-care tests can help alleviate these re-
source pressures. Microneedle diagnostic technologies, being minimally invasive, self-administrable, 
portable, cost-effective, and mass-producible, offer an attractive approach to rapid, decentralised point-
of-care infectious disease diagnosis. This is a nascent area of research, so development and manufac-
turing costs are difficult to predict. The vast majority of microneedle devices are fabricated from mate-
rials such as silicon, polymers, and metals using already well-established low-cost techniques including 
micromolding, machine milling, injection moulding, 3D printing, and micro-electromechanical systems 
manufacture [79], [80], most of which lend themselves to large-scale production. The development and 
manufacturing costs are likely to be offset by a reduction in the professional labour time, which is the 
primary cost associated with point-of-care testing [81], [82].  
Significant technical challenges also remain especially in terms of method validation and miniaturi-
sation of the detection backend, as well as regulatory and quality control during mass manufacture [83], 
despite the optimism offered by some examples of successful integration of on-chip analytical systems 
into microneedle platforms for other medical conditions (discussed above). Overcoming these technical 
challenges requires a concerted effort of research scientists, industrialists, and policymakers. More re-
sources need to be invested to spur the development of robust point-of-care devices, building on the 
strengths of current microneedle diagnostic technologies. Intensified research and development will 
mature the technologies needed to mass-produce microneedle diagnostic devices, which will further 
reduce the cost and make microneedle-based diagnostics more accessible, even in lower-income re-
gions.  
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